Midday Report: NovoCure (NVCR) Trades Higher June 23

Equities Staff  |

NovoCure Ltd (NASDAQ: NVCR) has climbed $3.92 (6.18%) and sits at $67.03, as of 12:05:36 est on June 23.

406,861 shares have been traded today.

The Company is up 4.26% over the last 5 days and shares fell 17.71% over the last 30 days.

NovoCure expects its next earnings on 2022-07-28.

For technical charts, analysis, and more on NovoCure visit the company profile.

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

To get more information on NovoCure Ltd and to follow the company's latest updates, you can visit the company's profile page here: NovoCure Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?

Market Movers

Sponsored Financial Content